caregiver
esra okuyan
Statü
Katýlým: 14.09.2006
Þehir: ankara
Ýlçe: çankaya
Bio ÖM
özel üye
176 Yanýtý Var
Gönderme Tarihi: - 11/09/2007 : 02:06:53 AM
--------------------------------------------------------------------------------
Long-term Antibiotic Treatment with Roxithromycin in Patients with Multiple Sclerosis
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17180590&query_hl=1& itool=pubmed_docsum
Dept. of Neurology, Westpfalz Medical Center, Kaiserslautern, Germany.
BACKGROUND:
There are conflicting results concerning an association between Chlamydia pneumoniae and MS. In the present study, we investigated a possible therapeutic option with antibiotics.
PATIENTS AND METHODS:
In our randomized, placebocontrolled double-blind study, 28 patients with the confirmed diagnosis of MS [61% relapsing-remitting MS (RR-MS), 32% secondary chronic-progressive MS (SP-MS) and 7% primary chronic progressive MS (PP-MS)] were treated over a time period of 12 months with three cycles of a 6-week oral antibiotic therapy with roxithromycin (300 mg per day) or placebo.
RESULTS:
No significant differences were observed in patients with RR-MS regarding the expanded disability status scale (EDSS) and the relapse rate when comparing treatment with roxithromycin and placebo.
CONCLUSION:
Our study shows that the patients with MS do not profit from a long-term antibiotic treatment with roxithromycin compared to placebo treatment.
A causative connection between bacterial infections with Chlamydia pneumoniae and MS therefore does seem very unlikely.
YABANCI DÝLÝ OLAN ARKADAÞLAR BÝZE BURDAN BÝLGÝLER AKTARIRSA SEVÝNÝRÝM:)sevgiyle
